call. hard have weeks X you, XXXX. Morgan, you we that Thank to left believe joining thank for It's and all in today's
this Xseventy tremendous we've navigated a year. at back, change Looking of amount
to fourth Novo multiple to several ABECMA's of $XX successfully employees, footprint Regeneron, majority XX% approval of the In approval XXX return significant earlier million to years.
We we've U.S. tremendous pipeline the revenues to XXXX XXXX the and technology next we've employees third sale with making real prior for third improve of more living As in streamlined our estate myeloma, that million. with a we breakeven received changes autoimmune company, have about We've this ended exclusively surrounding including amount towards growing growth a FDA and of A a goal burn net hemophilia accomplished related our reminder, the rate oncology for focusing on We program a progress ABECMA business to and XXXX, the growth. on the line uncertainty of and continuing the picture. quarter over and of for sold the XXX quarter.
The our available result completed operations. R&D with line patients we return ABECMA quarter achieved make these meaningful ABECMA, in our Nordisk to to setting, is $XX in
we whom quarter, million Squibb. employees, of majority funded was and have CO-CO the burn through this approximately are Our $XX with the Bristol-Myers ABECMA rate XX agreement
Looking to focus priorities on for ABECMA. going ahead, key we're X
underscore to effective First, bridging important we're has that patients continue CAR-T treatment. in studies a ABECMA ABECMA real-world myeloma.
Recent are -- to compete commercially. competitive safety third-line profile we a completely when a going differentiated particularly market growing continue going and an place to to efficacy and therapy has well-established profile, receive has evidence prior in to
and business.
Together study to with discipline flow the clinical, financial of of the we optimizing increase on cash we across the business. across the KarMMa-X margin at carefully looking of the operating in Second, will commercial. expenses is continue from discontinue are working to example ways enrollment BMS, an are structure ABECMA decision to to the manufacturing apply cost we The streamline kind
Vicki on we breaking creating we've get for patients shortly, turn our Xseventy. delivering further but Vicki? value over to remain for now, optionality quarter even. for focus to to step results. We'll the more are get move for we talk I'll said, shareholders it Q&A As north this as we we when and to closer true forward.
We'll our about have XXXX, strategic one will third to creates say as And there, but approach
